State-by-state and country-by-country guide to ibogaine legality: Texas/Arizona research funding, Costa Rica and Mexico's unscheduled status, and where medical prescribing is permitted.
No. Ibogaine is a Schedule I controlled substance under the federal Controlled Substances Act (21 U.S.C. § 812) — the federal government has determined it has no currently accepted medical use, a high potential for abuse, and lacks accepted safety for use under medical supervision. There is no FDA-approved ibogaine product and no state that has legalized ibogaine for personal use or clinical treatment.
What has changed is state-level research funding, not legal status. Texas appropriated $50 million for ibogaine clinical trials via Senate Bill 2308 (signed June 2025), backing the IMPACT consortium led by UTHealth Houston and UT Medical Branch at Galveston — see the full Texas SB 2308 guide. Arizona passed HB 2871, appropriating $5 million for ibogaine neuroscience research — see the Arizona HB 2871 guide. Kentucky saw legislative interest in 2024 that was ultimately not funded; no bill passed. None of these programs make ibogaine legal to possess or administer outside an FDA-authorized trial — a resident of Texas or Arizona has the same legal access today as a resident of any other state: an FDA-authorized clinical trial or travel abroad.
| Jurisdiction | Status | Details |
|---|---|---|
| Federal (all states) | Schedule I | Ibogaine has no accepted medical use under federal law. Research requires FDA IND authorization plus DEA Schedule I registration. No state can override federal scheduling. |
| Texas | Research funding (SB 2308) | $50 million appropriated June 2025 for the IMPACT consortium (UTHealth Houston, UTMB Health, plus Baylor, UT Austin, Texas Tech, Texas A&M). Funds FDA-authorized trials in opioid use disorder, TBI, and PTSD — does not legalize possession. |
| Arizona | Research funding (HB 2871) | $5 million appropriated for ibogaine neuroscience research. Does not create a treatment-access pathway outside authorized research. |
| Kentucky | No bill passed | 2024 legislative interest in ibogaine research funding was ultimately not funded. Ibogaine remains Schedule I in Kentucky with no state research program. |
| Oregon & Colorado | Schedule I | A common point of confusion: Oregon’s Measure 109 (2020) and Colorado’s Prop 122 / Natural Medicine Health Act (2022) created regulated legal-access frameworks for psilocybin specifically — neither program names or covers ibogaine. Ibogaine remains a Schedule I controlled substance in both states with no licensed access pathway. |
| All other states | Schedule I | Ibogaine is a Schedule I controlled substance with no state-level research funding or access program as of 2026. |
The countries below are the ones with a documented, sourced legal position on ibogaine. This is not an exhaustive list of every country in the world — it is limited to jurisdictions where we can point to a specific law, regulatory decision, or scheduling status.
| Country | Status | Details |
|---|---|---|
| Costa Rica | Uncontrolled | Ibogaine and iboga alkaloids are not listed on the controlled substance schedules of Costa Rica’s Ley sobre Estupefacientes (Law No. 8204), so operating an ibogaine clinic is legal. Uncontrolled does not mean regulated — there is no government oversight of clinic quality or safety protocols. Full detail: Costa Rica ibogaine legal guide. |
| Mexico | Not federally scheduled | Ibogaine does not appear on the controlled-substance schedules of Mexico’s General Health Law (Ley General de Salud), which is why Mexico hosts the world’s largest concentration of ibogaine treatment programs, clustered near Cancún, Tijuana, and Playa del Carmen. Mexico has no medical regulatory framework specific to ibogaine treatment. Full detail: Mexico ibogaine clinics guide. |
| Brazil | Decriminalized (therapeutic use) | ANVISA (Brazil’s health regulatory agency) decriminalized ibogaine for therapeutic use in 2017. This is a decriminalization of therapeutic use, not a full drug-approval pathway comparable to FDA clearance. |
| New Zealand | Prescription-only medicine | Ibogaine has been a prescription-only regulated medicine in New Zealand since 2010 — a physician can prescribe it, unlike in the United States, where no legal prescribing pathway exists outside an authorized clinical trial. |
| Portugal | Decriminalized (all drugs) | Since 2001, Portugal has decriminalized personal possession of all drugs, including ibogaine, as a public health measure. Possession of small quantities is an administrative offense referred to a dissuasion commission; this is a general decriminalization policy, not an ibogaine-specific medical framework, and no therapeutic access pathway exists. |
| Canada | Schedule III — research only | Ibogaine is a Schedule III controlled substance under Canada’s Controlled Drugs and Substances Act. Health Canada has not approved it as a therapeutic product under the Food and Drugs Act, so it cannot be legally manufactured, sold, or marketed for treatment. The Act’s Section 56 exemption power lets the Minister authorize a controlled substance for medical or scientific purposes on a case-by-case basis, and this is the mechanism Canadian institutions use to access ibogaine for research — it is not a general legal-access pathway, and no commercial ibogaine clinic operates lawfully in Canada under it. |
| South Africa | Unscheduled / permitted for medical use | Ibogaine is described as unscheduled or permitted for medical use in South Africa. We do not have a specific statute citation for this page beyond that general status — treat this row as directional and confirm with a South African regulatory source before relying on it for treatment planning. |
| United States | Schedule I | No accepted medical use federally. Texas and Arizona fund research (not access); Kentucky’s 2024 funding effort did not pass. See full detail above. |
Costa Rica and Mexico are not "legal" for ibogaine in the sense of having an approved medical framework — they are uncontrolled, meaning ibogaine simply was never added to either country’s drug schedules. That absence of prohibition, combined with no regulatory approval process to navigate, is what let a private clinic industry grow openly in both countries over the past decade. It also means clinic quality is entirely unregulated: the difference between a cardiac-safety-first clinic and a dangerous one comes down to the individual operator, not government oversight. See the best ibogaine treatment centers guide for how to evaluate a specific clinic.
No. Ibogaine remains Schedule I under US federal law regardless of its legal status in Costa Rica, Mexico, or any other country. Carrying ibogaine across the US border is a federal drug trafficking offense. US health insurance — including Medicare, Medicaid, and VA benefits — does not cover ibogaine treatment abroad. Veterans accessing ibogaine through Texas SB 2308 must use state-designated research sites; traveling internationally for treatment does not qualify for that funding.
Ibogaine is Schedule I federally with no state that has legalized it for personal use or clinical treatment. Texas (Senate Bill 2308, $50 million, June 2025) and Arizona (House Bill 2871, $5 million) have appropriated state funds for ibogaine clinical research through the IMPACT consortium and similar programs — that funds FDA-authorized trials, it does not make ibogaine legal to possess or administer outside a trial. Kentucky considered funding in 2024 but no bill passed.
Ibogaine is not listed on the controlled-substance schedules of Mexico's General Health Law (Ley General de Salud), so it is not federally scheduled there — which is why Mexico hosts the world's largest concentration of ibogaine treatment clinics, clustered near Cancún, Tijuana, and Playa del Carmen. Mexico has no medical regulatory framework specific to ibogaine, so clinic quality and safety protocols vary clinic to clinic.
Yes, in the sense that it is uncontrolled: ibogaine and iboga alkaloids do not appear on Costa Rica's controlled substance schedules under Law No. 8204 (Ley sobre Estupefacientes), so operating an ibogaine clinic there is legal. Uncontrolled does not mean regulated — there is no government oversight of clinic quality or safety standards.
No country has a full drug-approval pathway for ibogaine comparable to FDA clearance. Brazil's health regulator ANVISA decriminalized ibogaine for therapeutic use in 2017. New Zealand has allowed prescription-only ibogaine as a regulated medicine since 2010. Portugal decriminalized personal possession of all drugs, including ibogaine, in 2001, as a general public-health policy rather than an ibogaine-specific medical framework. Canada and South Africa are generally described as unscheduled or permitting medical use, though we do not have a specific statute citation for either beyond that general status.
No. Ibogaine remains Schedule I under US federal law regardless of its legal status abroad. Carrying ibogaine across the US border is a federal drug trafficking offense. US health insurance, including Medicare, Medicaid, and VA benefits, does not cover ibogaine treatment abroad, and traveling internationally for treatment does not qualify for Texas SB 2308 research funding, which is limited to state-designated research sites.
Get Ibogaine research & policy updates
New trials, FDA decisions, and legal changes for Ibogaine — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.